Details

Autor(en) / Beteiligte

• Devaraj, Suma
• Panda, Soumya Surath
• Arun, Gourab
• Panda, Adya Kinkar
• Mohapatra, Debahuti
• Moharana, Lalatendu
• Kolluri, Spoorthy
• Kilaru, Sindhu
• Mohanty, Swati Sucharita
• Biswas, Ghanashyam

Titel

Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature

Ist Teil von

• Indian journal of medical and paediatric oncology, 2023-11

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract Anaplastic lymphoma kinase inhibitors (ALKi) are the standard of care for metastatic ALK-rearranged nonsmall cell lung cancer (NSCLC). Though most patients respond well to ALK, seldom there are instances where the disease progresses rapidly. Here, we present a case of a 41-years-old male diagnosed as NSCLC with ALK rearrangement. Despite being started on first- and second-generation ALK-targeted therapy, he had rapid disease progression ultimately succumbing to the disease within 3 months of diagnosis. We suspect that our patient has a variant of ALK, making him resistant to both first- and second-line targeted therapy. Subjecting such nonresponders to next-generation sequencing and identifying the variants might help to recognize a subset of patients among ALK+ NSCLC who will need intense monitoring and early institution of other therapies for a better outcome.